These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 36400328

  • 21. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
    Tang TY, Nichetti F, Kaplan B, Lonardi S, Pietrantonio F, Salvatore L, Vivaldi C, Rimassa L, de Braud F, Rizzato MD, Pavlick D, Chu R, Danner De Armas A, Sharaf R, Sokol E, Rodon Ahnert J, Ross JS, Javle M, Niger M.
    Clin Cancer Res; 2023 Dec 01; 29(23):4853-4862. PubMed ID: 37773629
    [Abstract] [Full Text] [Related]

  • 22. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A, Lamarca A, Hubner RA, McNamara MG, Valle JW.
    Expert Opin Investig Drugs; 2021 Apr 01; 30(4):301-307. PubMed ID: 33683991
    [Abstract] [Full Text] [Related]

  • 23. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M, Heumann T, Goff L, Agarwal R.
    Chin Clin Oncol; 2023 Apr 01; 12(2):14. PubMed ID: 36946186
    [Abstract] [Full Text] [Related]

  • 24. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
    Cosgrove DP, Reese ES, Fulcher NM, Bobiak SS, Lamy FX, Allignol A, Boyd M, Mahmoudpour SH.
    Cancer Med; 2023 Feb 01; 12(4):4195-4205. PubMed ID: 36263922
    [Abstract] [Full Text] [Related]

  • 25. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
    Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Uson Junior PLS, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L.
    Ann Oncol; 2022 Dec 01; 33(12):1269-1283. PubMed ID: 36089135
    [Abstract] [Full Text] [Related]

  • 26. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
    Lodl E, Ramnaraign B, Sahin I, Wheeler S.
    J Oncol Pharm Pract; 2023 Jul 01; 29(5):1206-1217. PubMed ID: 37097888
    [Abstract] [Full Text] [Related]

  • 27. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN.
    Hepatology; 2021 Oct 01; 74(4):1914-1931. PubMed ID: 33884649
    [Abstract] [Full Text] [Related]

  • 28. Systemic therapies for intrahepatic cholangiocarcinoma.
    Kelley RK, Bridgewater J, Gores GJ, Zhu AX.
    J Hepatol; 2020 Feb 01; 72(2):353-363. PubMed ID: 31954497
    [Abstract] [Full Text] [Related]

  • 29. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
    Roth GS, Verlingue L, Sarabi M, Blanc JF, Boleslawski E, Boudjema K, Bretagne-Bignon AL, Camus-Duboc M, Coriat R, Créhange G, De Baere T, de la Fouchardière C, Dromain C, Edeline J, Gelli M, Guiu B, Horn S, Laurent-Croise V, Lepage C, Lièvre A, Lopez A, Manfredi S, Meilleroux J, Neuzillet C, Paradis V, Prat F, Ronot M, Rosmorduc O, Cunha AS, Soubrane O, Turpin A, Louvet C, Bouché O, Malka D.
    Eur J Cancer; 2024 May 01; 202():114000. PubMed ID: 38493667
    [Abstract] [Full Text] [Related]

  • 30. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER, Sia D.
    Adv Cancer Res; 2022 May 01; 156():167-199. PubMed ID: 35961699
    [Abstract] [Full Text] [Related]

  • 31. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
    Schweitzer N, Vogel A.
    Best Pract Res Clin Gastroenterol; 2015 Apr 01; 29(2):345-53. PubMed ID: 25966433
    [Abstract] [Full Text] [Related]

  • 32. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK, Bibeau K, Schultz N, Yaqubie A, Millang B, Ren H, Féliz L.
    Target Oncol; 2022 Sep 01; 17(5):517-527. PubMed ID: 36114955
    [Abstract] [Full Text] [Related]

  • 33. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy.
    Demols A, Bucalau AM, Mans L.
    Curr Opin Oncol; 2022 Jul 01; 34(4):403-411. PubMed ID: 35837710
    [Abstract] [Full Text] [Related]

  • 34. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A, Segatto O, Stenzinger A, Saborowski A.
    Annu Rev Med; 2023 Jan 27; 74():293-306. PubMed ID: 36170665
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Immune checkpoint inhibitors in cholangiocarcinoma.
    Beri N.
    Immunotherapy; 2023 May 27; 15(7):541-551. PubMed ID: 37096964
    [Abstract] [Full Text] [Related]

  • 39. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 40. Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments.
    Valery M, Vasseur D, Fachinetti F, Boilève A, Smolenschi C, Tarabay A, Antoun L, Perret A, Fuerea A, Pudlarz T, Boige V, Hollebecque A, Ducreux M.
    Cancers (Basel); 2023 Sep 06; 15(18):. PubMed ID: 37760415
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.